{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:39:59Z","timestamp":1787755199124,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bisphosphonates are proven to be effective in obviating the need for surgical intervention in osteonecrosis of the femoral head. However, the late onset of pain relief hampers compliance. We present the clinical and radiographic outcome of a combination therapy compared with alendronate-only therapy for the management of osteonecrosis of the femoral head.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The data of patients diagnosed with osteonecrosis of the femoral head from January 2001 to January 2017 were retrospectively analyzed. The first group, the alendronate treatment group, comprised 432 hips (358 patients) diagnosed from January 2001 to January 2009 and treated with 10-mg oral alendronate daily for 3 years. The second group, the combination treatment group, comprised 442 hips (386 patients) diagnosed from February 2009 to January 2017 and treated with a combination therapy of 35-mg oral alendronate twice weekly and 5-mg intravenous zoledronic acid once annually for 3 years. Clinical assessment was performed using the Harris hip score, the visual analog scale (VAS) pain score, and the clinical failure rate. Radiographic assessment was performed for progression and collapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the alendronate treatment group, at a mean follow-up of 129.6 months (range, 60 to 220 months), 74.5% did not require a surgical procedure, and, in the combination treatment group, at a mean follow-up of 69 months (range, 37 to 105 months), 88.9% did not require a surgical procedure. The clinical failure rate at 3 years was 4% for stage I, 11% for stage II, and 29% for stage III in the alendronate treatment group, and it was 5% for stage I, 9% for stage II, and 32% for stage III in the combination treatment group. Patients in the combination treatment group had a significantly better improvement in VAS score at 6 weeks (from 7.10 to 3.66) compared with patients in the alendronate treatment group (from 7.93 to 7.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study shows that both oral alendronate-only therapy and bisphosphonate combination therapy retard the progression of disease, reduce the rate of collapse, and, hence, reduce the need for joint replacement surgery. However, bisphosphonate combination therapy offers earlier improvement in pain and functional scores compared with oral alendronate therapy only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      Therapeutic\n                      <jats:underline>Level III<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.oa.21.00042","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T06:00:06Z","timestamp":1639807206000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["A Paradigm Shift in Osteonecrosis Treatment with Bisphosphonates"],"prefix":"10.2106","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-2019","authenticated-orcid":false,"given":"Sanjay Agarwala","family":"D(Orth)","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Vijayvargiya","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10]]},"reference":[{"issue":"4","key":"R1-20240801","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1302\/0301-620X.47B4.612","article-title":"Idiopathic necrosis of the femoral head in adults","volume":"47","author":"Merle D\u2019Aubign\u00e9","year":"1965","journal-title":"J Bone Joint Surg Br"},{"issue":"277","key":"R2-20240801","first-page":"12","article-title":"Nontraumatic avascular necrosis of the femoral head. Past, present, and future","author":"Arlet","year":"1992","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"R3-20240801","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2106\/JBJS.19.01271","article-title":"Nontraumatic osteonecrosis of the femoral head: where do we stand today? A 5-year update","volume":"102","author":"Mont","year":"2020","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"R4-20240801","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13018-019-1359-7","article-title":"The efficacy and safety of core decompression for the treatment of femoral head necrosis: a systematic review and meta-analysis","volume":"14","author":"Hua","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"R5-20240801","first-page":"949","article-title":"Study of alendronate in avascular necrosis of bone","volume":"49","author":"Agarwala","year":"2001","journal-title":"J Assoc Physicians India"},{"issue":"7","key":"R6-20240801","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.arth.2010.11.010","article-title":"Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years","volume":"26","author":"Agarwala","year":"2011","journal-title":"J Arthroplasty"},{"issue":"3","key":"R7-20240801","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/keh481","article-title":"Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study","volume":"44","author":"Agarwala","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"R8-20240801","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/41.3.346-a","article-title":"Alendronate in the treatment of avascular necrosis of the hip","volume":"41","author":"Agarwala","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"R9-20240801","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1302\/0301-620X.91B8.21518","article-title":"The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years","volume":"91","author":"Agarwala","year":"2009","journal-title":"J Bone Joint Surg Br"},{"issue":"10","key":"R10-20240801","first-page":"2155","article-title":"The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study","volume":"87","author":"Lai","year":"2005","journal-title":"J Bone Joint Surg Am"},{"issue":"443","key":"R11-20240801","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.blo.0000194078.32776.31","article-title":"Does alendronate prevent collapse in osteonecrosis of the femoral head?","volume":"443","author":"Nishii","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"R12-20240801","first-page":"1","article-title":"Bisphosphonate combination therapy in the management of postchemotherapy avascular necrosis of the femoral head in adolescents and young adults: a retrospective study from India","volume":"4","author":"Agarwala","year":"2018","journal-title":"J Glob Oncol"},{"issue":"1","key":"R13-20240801","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13018-019-1152-7","article-title":"Bisphosphonate combination therapy for non-femoral avascular necrosis","volume":"14","author":"Agarwala","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"R14-20240801","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JEP.S7823","article-title":"Current and emerging therapies for the treatment of osteoporosis","volume":"2","author":"Waalen","year":"2010","journal-title":"J Exp Pharmacol"},{"issue":"5","key":"R15-20240801","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"issue":"9","key":"R16-20240801","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/pbc.24563","article-title":"Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis","volume":"60","author":"Padhye","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20240801","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-3-19","article-title":"Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats","volume":"3","author":"Astrand","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"R19-20240801","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2106\/00004623-196951040-00012","article-title":"Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation","volume":"51","author":"Harris","year":"1969","journal-title":"J Bone Joint Surg Am"},{"key":"R20-20240801","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2106\/00004623-196446020-00004","article-title":"Idiopathic avascular necrosis of the head of the femur. A study of fifty-two cases","volume":"46","author":"Patterson","year":"1964","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"R23-20240801","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2106\/00004623-199503000-00018","article-title":"Non-traumatic avascular necrosis of the femoral head","volume":"77","author":"Mont","year":"1995","journal-title":"J Bone Joint Surg Am"},{"issue":"4","key":"R25-20240801","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0883-5403(06)80036-7","article-title":"The natural history of the silent hip in bilateral atraumatic osteonecrosis","volume":"8","author":"Bradway","year":"1993","journal-title":"J Arthroplasty"},{"issue":"277","key":"R26-20240801","first-page":"73","article-title":"The fate of nontraumatic avascular necrosis of the femoral head. A radiologic classification to formulate prognosis","author":"Ohzono","year":"1992","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"R27-20240801","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/00016470410004157","article-title":"Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats","volume":"75","author":"T\u00e4gil","year":"2004","journal-title":"Acta Orthop Scand"},{"issue":"1","key":"R28-20240801","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bone.2005.12.019","article-title":"Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head","volume":"39","author":"Kim","year":"2006","journal-title":"Bone"},{"issue":"12","key":"R29-20240801","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00167-010-1106-4","article-title":"Possible beneficial effect of bisphosphonates in osteonecrosis of the knee","volume":"18","author":"Kraenzlin","year":"2010","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"issue":"1","key":"R30-20240801","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"issue":"8","key":"R31-20240801","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2106\/JBJS.F.00964","article-title":"Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents","volume":"89","author":"Ramachandran","year":"2007","journal-title":"J Bone Joint Surg Am"}],"container-title":["JBJS Open Access"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.OA.21.00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:08Z","timestamp":1787751548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.OA.21.00042"}},"subtitle":["A 20-Year Study"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.oa.21.00042","relation":{},"ISSN":["2472-7245"],"issn-type":[{"value":"2472-7245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}